Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.

[Back to Overview]  [IACM Homepage]

TitleCannabidiol in dystonic movement disorders.
Author(s)Sandyk R, Snider SR, Consroe P, Elias SM.
Journal, Volume, IssuePsychiatry Res. 1986 Jul;18(3):291.
Major outcome(s)Cannabidiol (CBD) reduced dystonic movements


Letter to the editors:
Evidence has recently accumulated to suggest that cannabidiol (CBD), a nonpsychoactive cannabinoid of marijuana, may be useful in the management of hyperkinetic movement disorders (Snider and Consroe, 1984, 1985). We have therefore tested the efficacy of CBD in two patients with dystonic movement disorders.
A 65-year-old woman had idiopathic spasmodic torticollis of 2 years’ duration. Her condition was characterized by a lateral pulling of her neck to the right, which occurred at a frequency of 8-12/minute. In addition, she had essential-type tremor affecting both hands, which was only partially relieved with atenolol (50mg/day). CBD (200mg, orally) produced an amelioration of the dystonic movements within 3 hours of the lateral neck movements to 2-4/minute. The patient’s improvement was confirmed by an evaluation of two independent neurologists.
A 31-year-old man had generalized torsion dystonia (dystonia musculorum deformans) of 20 years’ duration. He had obtained mild benefit from high doses (25-45 mg/day) of trihexyphenidyl, but was confirmed to a wheelchair. CBD (200 mg, orally) produced an amelioration of his symptoms (especially of his more severely affected right leg) within two hours of administration. Following CBD administration, he was able to walk without support, an effect that lasted about 24 hours. In both cases, CBD produced no adverse effects.
Cannabidiol (CBD) has been shown to have significant muscle relaxant effects and to reduce muscular spasms in humans (Petro, 1980). In rodents, CBD has been reported to reduce cholinergic transmission (Revuelta et al., 1978) and to increase turnover of gamma-aminobutyric acid (Revuelta et al., 1979). Acute administration of delta-tetradydrocannabinol to rats greatly potentiated the hypokinetic effect of reserpine (Moss et al., 1984), suggesting that this compound may have antidyskinetic properties in humans and that further studies of CBD in other hyperkinetic movement disorders in humans and warranted.

Dose(s)200 mg
Duration (days)
Participants2 case reports
DesignUncontrolled case report
Type of publicationMedical journal
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]